2500 Stock Overview Engages in the research, development, clinical development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Venus Medtech (Hangzhou) Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Venus Medtech (Hangzhou) Historical stock prices Current Share Price HK$5.62 52 Week High HK$14.94 52 Week Low HK$3.74 Beta 0.55 1 Month Change 0% 3 Month Change -0.71% 1 Year Change -61.61% 3 Year Change -92.66% 5 Year Change n/a Change since IPO -92.89%
Recent News & Updates
Venus Medtech (Hangzhou) Inc. Appoints Bing Zhu as the Chief Financial Officer Sep 11
Venus Medtech Venus-Vitae Completes First Two Implantations in SMART-ALIGN Pivotal Clinical Study Sep 05
Venus Medtech (Hangzhou) Inc. Announces Supervisor and Supervisory Committee Changes Aug 30
Venus Medtech (Hangzhou) Inc. to Report First Half, 2024 Results on Aug 30, 2024 Aug 20
Venus Medtech Venusp-Valve Completes First Implantation in Ide Pivotal Clinical Study in U.S Jun 15
Venus Medtech (Hangzhou) Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024 Mar 19 See more updates
Venus Medtech (Hangzhou) Inc. Appoints Bing Zhu as the Chief Financial Officer Sep 11
Venus Medtech Venus-Vitae Completes First Two Implantations in SMART-ALIGN Pivotal Clinical Study Sep 05
Venus Medtech (Hangzhou) Inc. Announces Supervisor and Supervisory Committee Changes Aug 30
Venus Medtech (Hangzhou) Inc. to Report First Half, 2024 Results on Aug 30, 2024 Aug 20
Venus Medtech Venusp-Valve Completes First Implantation in Ide Pivotal Clinical Study in U.S Jun 15
Venus Medtech (Hangzhou) Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024 Mar 19
Venus Medtech (Hangzhou) Inc. Announces That Wan Yee Joseph Lau, an Independent Non-Executive Director, the Chairman of the Nomination Committee and A Member of Each of the Remuneration and Assessment Committee and the Audit Committee of the Board, Passed Away Feb 07
Venus Medtech (Hangzhou) Inc. Appoints Fei Wang as the Chief Financial Officer Jan 05
Venus Medtech (Hangzhou) Inc. Approves Mr. Liqiao Ma as an Executive Director Dec 15
New minor risk - Share price stability Nov 30
Venus Medtech (Hangzhou) Inc. Announces Executive Changes Nov 21
No longer forecast to breakeven Oct 05 Venus Medtech (Hangzhou) Inc. Announces Appointment of Mr. Lim Housen (Lin Haosheng) as Joint Chief Executive Officer with Effect from September 22, 2023 Sep 23
No longer forecast to breakeven Sep 06
New minor risk - Profitability Sep 02
Venus Medtech (Hangzhou) Inc. to Report First Half, 2023 Results on Aug 31, 2023 Aug 22
New minor risk - Share price stability Jun 16
Founder recently bought HK$1.9m worth of stock Jun 13
Venus Medtech (Hangzhou) Inc., Annual General Meeting, Jun 30, 2023 Jun 09 Venus Medtech (Hangzhou) Inc. Announces Resignation of Haiyue Ma as Joint Company Secretary
Forecast to breakeven in 2025 Apr 03
Less than half of directors are independent Feb 01
Venus Medtech (Hangzhou) Inc. Announces Board Changes Jan 31
Insider recently sold HK$5.7m worth of stock Jan 14
Venus Medtech (Hangzhou) Inc. Announces Resignation of Lim Hou-Sen as an Executive Director and Nisa Bernice Wing-Yu Leung as Non-Executive Director and Vice Chairwoman Dec 14
Less than half of directors are independent Nov 16
First half 2022 earnings released: CN¥0.46 loss per share (vs CN¥0.26 loss in 1H 2021) Oct 03
Venus Medtech (Hangzhou) Inc. Announces Change of Employee Representative Supervisor and Chairperson of the Supervisory Committee Sep 02
First half 2022 earnings released: EPS: CN¥0 (vs CN¥0.26 loss in 1H 2021) Sep 02
Venus Medtech (Hangzhou) Inc. Announces Change of Employee Representative Supervisor and Chairperson of the Supervisory Committee Sep 01
Venus Medtech (Hangzhou) Inc. to Report First Half, 2022 Results on Aug 31, 2022 Aug 20
China's National Medical Products Administration Approves Venusp-Valve, Venus Medtech's In-House Developed Innovative Transcatheter Pulmonic Valve Replacement System Jul 14
Venus Medtech (Hangzhou) Inc. Announces First American Patient Treated with VenusP-Valve Under Compassionate Use Jun 23
Less than half of directors are independent Apr 27
Venus Medtech (Hangzhou) Inc. Announces Expandable Bioprosthetic Dry Tissue Valve Venus-Neo Completed First Clinical Application Apr 13
No longer forecast to breakeven Apr 06
Forecast breakeven date pushed back to 2023 Apr 02
Venus Medtech (Hangzhou) Inc., Annual General Meeting, May 30, 2022 Apr 01
Venus Medtech (Hangzhou) Inc. to Report Fiscal Year 2021 Results on Mar 31, 2022 Mar 23
Venus Medtech (Hangzhou) Inc. Appoints Amir Gross as Head of Venus Global Heart Valve Innovation Center Mar 03
Venus Medtech (Hangzhou) Inc. Announces Completion of Global First Clinical Application of Venus-Powerx Dec 23
Venus Medtech (Hangzhou) Inc. Announces Venus Vitae, Balloon-Expandable Dry Tissue Tavr System Successfully Completed the First Two Implantations in the Fim Clinical Trial Dec 21
Venus Medtech (Hangzhou) Inc. (SEHK:2500) commences an Equity Buyback Plan for 43,170,744 shares, representing 9.79% of its issued share capital, under the authorization approved on May 21, 2021. Dec 09
Forecast to breakeven in 2022 Sep 13
Forecast to breakeven in 2022 Sep 11
First half 2021 earnings released: CN¥0.26 loss per share (vs CN¥0.11 loss in 1H 2020) Sep 04
Forecast to breakeven in 2022 Sep 03
GM & Executive Director recently bought HK$35m worth of stock Jul 29
GM & Executive Director recently bought HK$6.0m worth of stock Jul 03
GM & Executive Director recently bought HK$30m worth of stock Jun 24
Full year 2020 earnings released: CN¥0.45 loss per share (vs CN¥1.22 loss in FY 2019) Apr 24
Full year 2020 earnings released: CN¥0.45 loss per share (vs CN¥1.22 loss in FY 2019) Apr 02
Venus Medtech (Hangzhou) Inc. to Report Fiscal Year 2020 Results on Mar 31, 2021 Mar 20
Venus Medtech (Hangzhou) Inc. has completed a Follow-on Equity Offering in the amount of HKD 1.444843 billion. Jan 31
GM & Executive Director recently sold HK$304m worth of stock Jan 22
Venus Medtech (Hangzhou) Inc. Announces its CEP Device, TriGUARD3, Completes its First Clinical Application in the PRC Jan 22
Venus Medtech (Hangzhou) Inc. Announces Change of Joint Company Secretary Jan 19
COO, CTO & Executive Director recently sold HK$280m worth of stock Jan 05
COO, CTO & Executive Director recently sold HK$193m worth of stock Jan 01 Shareholder Returns 2500 HK Medical Equipment HK Market 7D 0% -3.6% -2.4% 1Y -61.6% -29.2% 16.2%
See full shareholder returns
Return vs Market: 2500 underperformed the Hong Kong Market which returned -16.7% over the past year.
Price Volatility Is 2500's price volatile compared to industry and market? 2500 volatility 2500 Average Weekly Movement n/a Medical Equipment Industry Average Movement 8.1% Market Average Movement 8.2% 10% most volatile stocks in HK Market 16.5% 10% least volatile stocks in HK Market 3.7%
Stable Share Price: 2500 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 2500's volatility change over the past year.
About the Company Venus Medtech (Hangzhou) Inc. engages in the research, development, clinical development, manufacturing, and commercialization of transcatheter heart valve medical devices in Mainland China and internationally. The company’s products include VenusA-Valve, a transcatheter aortic heart valve replacement (TAVR) product to treat severe aortic stenosis; VenusP-Valve is a transcatheter pulmonary valve system to treat the dysfunction of right ventricular outflow tract; V8/TAV8 balloon aortic valvuloplasty catheter systems; and TriGUARD3, a cerebral embolic protection device for minimizing the risk of brain damage and prevent cerebral embolism during TAVR and other structural heart disease surgeries. It also develops VenusA-Plus and VenusA-Pilot, which are TAVR product candidates; transcatheter mitral and tricuspid valve replacement products; Liwen RF ablation system for the treatment of hypertrophic cardiomyopathy; and renal denervation for the treatment of hypertension.
Show more Venus Medtech (Hangzhou) Inc. Fundamentals Summary How do Venus Medtech (Hangzhou)'s earnings and revenue compare to its market cap? 2500 fundamental statistics Market cap HK$2.46b Earnings (TTM ) -HK$1.31b Revenue (TTM ) HK$491.35m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 2500 income statement (TTM ) Revenue CN¥452.11m Cost of Revenue CN¥101.03m Gross Profit CN¥351.07m Other Expenses CN¥1.56b Earnings -CN¥1.21b
Last Reported Earnings
Jun 30, 2023
Earnings per share (EPS) -2.76 Gross Margin 77.65% Net Profit Margin -267.18% Debt/Equity Ratio 23.4%
How did 2500 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/02/19 01:17 End of Day Share Price 2023/11/22 00:00 Earnings 2023/06/30 Annual Earnings 2022/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Venus Medtech (Hangzhou) Inc. is covered by 12 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Wai Chak Yuen BOCI Research Ltd. Jin Zhang China International Capital Corporation Limited Haoyuan Zhang China Merchants Securities (HK) Co., Ltd
Show 9 more analysts 
